💥The following paper: "Investigational Drug Treatments for Triple-Negative Breast Cancer" is published in the Journal of Personalized Medicine MDPI at: https://lnkd.in/gUTce5aJ We invite you to read this paper at the above link. And also hope that you could consider JPM (https://lnkd.in/g3jxwN_H) when submitting your next paper. #personalizedmedicine #precisionmedicine #breastcancer
Jane Jin’s Post
More Relevant Posts
-
MK-Bhan Young Research Fellow | Scientist C/Assistant Professor | Regional Centre for Biotechnology, DBT, GOI
Dear All, I am excited to share our recent publication entitled "Folate functionalized multifunctional CuO@PHBV@PDA nanoplatform for pH-Responsive dual drug delivery and ROS-driven apoptosis in breast cancer" in the Journal of Drug Delivery Science and Technology (I.F: 5.0). #drugdelivery #nanomedicine #cancertherapy #breastcancer Check out the link below:
Folate functionalized multifunctional CuO@PHBV@PDA nanoplatform for pH-Responsive dual drug delivery and ROS-driven apoptosis in breast cancer
sciencedirect.com
-
First-line treatment with ivonescimab (AK112; SMT112) monotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) monotherapy in patients with locally advanced or metastatic, PD-L1–positive non–small cell lung cancer (NSCLC), meeting the primary end point of the phase 3 HARMONi-2 trial (NCT05499390)OncLive https://lnkd.in/gj-HGWQP
First-Line Ivonescimab Improves PFS vs Pembrolizumab in PD-L1+ NSCLC in China
onclive.com
-
A paper in the Journal of Pharmacokinetics and Pharmacodynamics used a PBPK model to quantify the affects of drug interactions with combination breast cancer therapy (docetaxel, cyclophosphamide, and epirubicin). PBPK = physiologically based pharmacokinetic Link to Abstract: https://bit.ly/4cJlvP4 | #DrugDrugInteraction #CancerTreatments #Docetaxel #Cyclophosphamide #Epirubicin #PharmacokineticModels Springer Nature Group
Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions - Journal of Pharmacokinetics and Pharmacodynamics
link.springer.com
-
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
stocktitan.net
-
At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ("ASCO GI"), CARsgen presented a poster with study results for satricabtagene autoleucel ("satri-cel", R&D code: CT041, an autologous CAR-T product candidate against Claudin18.2), which include the dose escalation results of the Phase 1b ELIMYN18.2 study (Cohort A) in gastric/gastroesophageal (GC/GEJ) or pancreatic cancer (PC) in the US. https://lnkd.in/gCHDQ-af #cartcelltherapy #gastriccancer #pancreaticcancer
CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting
prnewswire.com
-
Combining this agent with sotorasib has demonstrated improvements vs sotorasib monotherapy by yielding deeper tumor regressions and reducing the occurrence of disease relapse based on preclinical proof-of-concept data. https://lnkd.in/gJYkBpcJ #NSCLC #cancer #oncology
FDA Grants FTD to Avutometinib/Sotorasib in KRAS G12C–Mutated NSCLC
cancernetwork.com
-
A new option for synovial sarcoma!
I'm excited to share a major breakthrough in cancer treatment: Adaptimmune's TECELRA® (afamitresgene autoleucel) has received U.S. FDA accelerated approval. This innovative engineered cell therapy is the first of its kind approved for a solid tumor, specifically advanced synovial sarcoma. This approval is a testament to the incredible dedication and innovation in the biotech field, offering new hope and treatment options for patients facing this challenging diagnosis. Congratulations to the Adaptimmune team for this remarkable achievement! For more information, read the full announcement: https://lnkd.in/dcKM9Cbt #HealthcareInnovation #CancerTreatment #Biotechnology #FDAApproval
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
adaptimmune.com
-
𝙀𝙛𝙛𝙞𝙘𝙖𝙘𝙮 𝙖𝙣𝙙 𝙨𝙖𝙛𝙚𝙩𝙮 𝙤𝙛 𝙖𝙣𝙡𝙤𝙩𝙞𝙣𝙞𝙗 𝙥𝙡𝙪𝙨 𝙥𝙚𝙣𝙥𝙪𝙡𝙞𝙢𝙖𝙗 𝙖𝙨 𝙨𝙚𝙘𝙤𝙣𝙙-𝙡𝙞𝙣𝙚 𝙩𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙛𝙤𝙧 𝙨𝙢𝙖𝙡𝙡 𝙘𝙚𝙡𝙡 𝙡𝙪𝙣𝙜 𝙘𝙖𝙣𝙘𝙚𝙧: 𝘼 𝙢𝙪𝙡𝙩𝙞𝙘𝙚𝙣𝙩𝙚𝙧, 𝙤𝙥𝙚𝙣-𝙡𝙖𝙗𝙚𝙡, 𝙨𝙞𝙣𝙜𝙡𝙚-𝙖𝙧𝙢 𝙥𝙝𝙖𝙨𝙚 𝙄𝙄 𝙩𝙧𝙞𝙖𝙡. A combination of #anlotinib and #penpulimab is a promising and safe #secondlinetherapy for patients with #smallcelllungcancer who face instances of first-line standard #chemotherapy failures. Read more in this #CancerPathogenesisAndTherapy article: https://lnkd.in/ezydRnfu
Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
sciencedirect.com
-
The results of NRG ONCOLOGY, The GOG Foundation, Inc, RTOG Foundation, #0724 at #ASCO24! #Chemoradiotherapy Plus Adjuvant #Chemotherapy for High-Risk #CervicalCancer After Radical Hysterectomy. From Oncology Learning Network. #gyncsm #clinicaltrial
Chemoradiotherapy Plus Adjuvant Chemotherapy for High-Risk Cervical Cancer After Radical Hysterectomy
hmpgloballearningnetwork.com
-
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
euoncology.europeanurology.com